MHE May 2025

In this final interview of a three-part video series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, told MHE, in response to our recent annual Pharmacy Survey results, that FDA drug approval delays due to government cuts are happening but not widespread yet. He added that early signs and staffing challenges suggest the situation could worsen over time.

Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his insights on the results of Managed Healthcare Executive’s annual Pharmacy Survey in this part-two interview of a three-video series. In the interview, he discussed survey respondents’ views on Alzheimer’s disease as a leading driver of rising U.S. drug spending over the next three years. More than 100 healthcare industry experts took part in this year’s survey.

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers can afford to cover them and about wasteful prescriptions.

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy Survey results. In this interview, he gave his thoughts on respondents’ answers regarding new treatments that are most likely to significantly impact payer budgets this year and early next. Over 100 healthcare industry experts participated in this year’s survey.

Nearly two-thirds expect to see delays related to staffing cuts at the FDA.

The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news

The new administration bumped up 2026 rates for Medicare Advantage plans. an early sign that it may treat the plans favorably.

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of treatment high.

Nirvana, a healthcare technology startup, uses artificial intelligence to better predict insurance coverage.

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx (suzetrigine) in January 2025.